Clinical trials: Phase I
Healthy, Elevated LDL-C
Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C
This is a Phase I, single-dose and multiple dose escalation clinical trial for HSK31679 conducted in chinese healthy volunteers and LDL-C elevated subjects.
- Trial name
- NCT05531097
- Testing
- HSK31679
- Where
- 2 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Solid Tumor
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting.
- Trial name
- NCT02590952
- Testing
- Epitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Hutchison Medipharma Limited
COVID-19
Clinical Trial of SARS-CoV-2 mRNA Vaccine in China
This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.
- Trial name
- NCT05364047
- Testing
- Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009
- Where
- 3 sites in China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Healthy
Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects
Drug drug interaction study between PF-05221304 and PF-06865571
- Trial name
- NCT03534648
- Testing
- PF-06865571 administered Day 7-14, PF-06865571 administered Day 1-14, PF-05221304 administered Day 1-14
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Renal Impairment
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
- Trial name
- NCT06318676
- Testing
- Mezigdomide
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Breast Cancer
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer.
- Trial name
- NCT02569489
- Testing
- HBI-8000, Trastuzumab, Paclitaxel
- Sponsor
- HUYABIO International, LLC.
Pharmacokinetic
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
Single center, randomized, double-blinded, placebo-controlled, single ascending-dose study for the evaluation of the safety, tolerability, and PK following single oral doses of INV-101.
- Trial name
- NCT04531150
- Testing
- INV-101
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inversago Pharma Inc.
Breast Neoplasms
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
- Trial name
- NCT01097460
- Testing
- MM-111 + Herceptin
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Merrimack Pharmaceuticals
Safety, Tolerability
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
The purpose of this study is to evaluate the safety and tolerability of single and multiple oral dosing of MLN3126 in ascending doses in healthy non-Japanese and Japanese participants.
- Conditions
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT02209506
- Testing
- MLN3126
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Takeda
Epstein-Barr Virus
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.
- Trial name
- NCT07478952
- Testing
- mRNA-1189
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Neoplasms, Plasma Cell, Neoplasms by Histologic Type
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple…
- Conditions
- Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders
- Trial name
- NCT06271252
- Testing
- OriCAR-017
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- OriCell Therapeutics Co., Ltd.
Healthy Volunteers
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body.
- Trial name
- NCT06968338
- Testing
- ARGX-213
- Where
- Canada
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- argenx
Metastatic Colorectal Cancer
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the…
- Trial name
- NCT01075048
- Testing
- Tivantinib, Cetuximab, Irinotecan
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 131 people
- Sponsor
- Daiichi Sankyo
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07160608
- Testing
- Tarperprumig
- Where
- 57 sites in Argentina, Australia and 12 more
- Volunteers
- 78 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy Volunteer
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
This study is a randomized Trastuzumab-controlled double-blind parallel-group study.
- Trial name
- NCT02100917
- Testing
- DMB-3111, trastuzumab
- Where
- Japan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Acute Leukemia
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-revumenib in participants with acute leukemia.
- Trial name
- NCT05406817
- Testing
- Revumenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Syndax Pharmaceuticals
Neurofibromatosis Type 1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints.
- Trial name
- SPRINKLE (NCT05309668)
- Testing
- Selumetinib granule formulation, Selumetinib capsule formulation
- Where
- 16 sites in United States, Germany and 5 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Cognition Disorders
This is a Single Ascending Dose Tolerance Study
This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)
- Trial name
- NCT01133574
- Testing
- SLV354 capsules
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Abbott
Healthy Volunteers
A Phase I Study of RC1416 Injection
This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.
- Trial name
- NCT06067490
- Testing
- RC1416(SAD)
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.